Abstract

Systematic review and network meta-analysis of antivirals for treatment of hepatitis C Virus genotype 6

Chaiwat Tungsakul

 Papichaya Wannadee 

Nattawat Teerawattanapong

Saksakon Paratsaphan 

meta-analysis, hepatitis C virus genotype 6, sustained virological response

Introduction: Hepatitis C virus genotype 6 is primarily clustered in East Asia and Southeast Asia. Effectiveness of antivirals in this genotype are limited. Our study aims to define the best effectiveness of antiviral regimens in HCV genotype 6. The endpoints of study are sustained virological response (SVR) 12 and 24 weeks after treatment stopped (SVR12 and SVR24, respectively) and safety profile using network meta-analysis. Methods: Clinical trials were searched using defined MeSH in PubMed, Cochrane Library and Web of Science (September to October 2019). Cochrane Risk of Bias Tool 2.0 was used to assess the quality of the articles. The pooled estimated of SVR was extracted via systematic review and analyzed using network meta-analysis commands in STATA 14.0 package. Results: The pooled estimated SVR12 rate of 12 weeks Grazoprevir combined with Elbasvir ± Ribavirin treatment was 74%. Rates of SVR24 of Pegylated interferon with Ribavirin for 24 and 48 weeks were 73% and 79%, respectively. Either Sofosbuvir combined with Velpatasvir ± Voxilaprevir or Sofosbuvir with Ribavirin resulted in 100% SVR12 at any duration of treatment. The most common side effects of antivirals were headache and fatigue. Conclusion: Sofosbuvir combined with Ribavirin or Velpatasvir was the most effective regimen.